Meeting
2020 ASCO Virtual Scientific Program
Plasma next-generation sequencing (NGS) in advanced non-small cell lung cancer (aNSCLC) patients (pts) treated with immune checkpoint inhibitors (ICIs): Impact of STK11 and TP53 mutations on outcome.
Authors
Alberto Pavan
Medical Oncology 2, Istituto Oncologico Veneto IOV-IRCCS, Padua, Italy
Alberto Pavan , Elisabetta Zulato , Lorenzo Calvetti , Alessandra Ferro , Giorgia Nardo , Alice Boscolo , Ilaria Attili , Stefano Frega , Alessandro Dal Maso , Giulia Pasello , Valentina Guarneri , Giuseppe Aprile , Pier Franco Conte , Stefano Indraccolo , Laura Bonanno
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Circulating Biomarkers
Citation
J Clin Oncol 38: 2020 (suppl; abstr 3046)
DOI
10.1200/JCO.2020.38.15_suppl.3046
Abstract #
3046
Poster Bd #
110
Abstract Disclosures
Similar Posters
Poster
2019 ASCO-SITC Clinical Immuno-Oncology Symposium
Targeted sequencing of plasma cell-free DNA to predict response to PD1 inhibitors in advanced non-small cell lung cancer.
First Author: Nicolas Guibert
Poster
2023 ASCO Annual Meeting
Clinical and genomic predictors of response and toxicity to sotorasib in a real-world cohort of patients with advanced KRAS G12C-mutant non-small cell lung cancer.
First Author: Kathryn C. Arbour
Poster
2023 ASCO Annual Meeting
Molecular characterization of resistance to immune checkpoint inhibitor and chemotherapy treatment in advanced non-small cell lung cancer.
First Author: Jordan Kardos
Poster
2022 ASCO Annual Meeting
Molecular characterization of NF1-mutated NSCLC and clinical outcomes.
First Author: Christopher Gates